98%
921
2 minutes
20
Cardiomyopathy encompasses a range of diseases that severely affect the complex functions of the heart, involving structural and functional abnormalities, and is associated with high mortality. Recent studies have highlighted the critical role of ferroptosis in regulating oxidative stress and inflammation in cardiomyopathy. In this study, we established that the C6 S100A4+ SMCs subpopulation is critical by performing an integrated single-cell analysis of the known publicly available data GSE145154. We validated the role of S100A4 in SMCs through in vitro experiments, providing evidence for its potential as a therapeutic target. Furthermore, these cells interact with endothelial cells through the PTN-NCL pathway, influencing disease progression. Key transcription factors, including KLF2, FOS, FOSB, and JUNB, were identified. This key subpopulation, along with its associated signaling pathways, marker genes, stemness genes, and transcription factors, may offer new insights for preventing the onset and progression of cardiomyopathy, particularly ischemic cardiomyopathy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301475 | PMC |
http://dx.doi.org/10.1038/s41598-025-09928-6 | DOI Listing |
Front Cardiovasc Med
August 2025
Department of Ultrasonic Medicine, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Gap junctions (GJs) are critical structures for cardiac electrical signal conduction and synchronized contraction. Their fundamental components are transmembrane proteins from the connexin (Cx) family, which assemble into hexameric channels to form intercellular ion-permeable pathways, ensuring efficient electrical transmission and coordinated contraction between cardiac cells. Connexin 43 (Cx43), the most abundant connexin in the heart, serves as the primary constituent of ventricular gap junctions.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
August 2025
Institute of Biomedical Sciences, Faculty of Medicine, 8380000 Santiago, Chile.
Acute myocardial infarction (AMI) is one of the main causes of mortality worldwide. Currently, the most effective treatment is percutaneous coronary angioplasty (PCA). However, paradoxically, the restoration of blood flow induces myocardial reperfusion injury (MRI), contributing up to 50% of the final infarct size.
View Article and Find Full Text PDFCardiovasc Hematol Agents Med Chem
September 2025
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Pulmonary Hypertension (PH) is a significant contributor to cardiac mortality in Dilated Cardiomyopathy (DCM) patients. Inflammatory processes and oxidative stress play pivotal roles in the advancement of Pulmonary Hypertension (PH). The Monocyte-to-High-- Density-Lipoprotein Cholesterol Ratio (MHR), a newly identified biomarker indicative of inflammatory and oxidative stress, has not been extensively researched in the context of pulmonary hypertension, especially within the scope of dilated cardiomyopathy.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
September 2025
Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, New York, USA.
Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist in patients, with the development of AF often preceding HF decompensation. We sought to evaluate whether daily remote monitoring of ICD parameters could predict AF occurrence using machine learning techniques in a real-world cohort.
Methods: Data from patients with primary prevention ICDs transmitted daily to the Northwell centralized remote monitoring center between 2012 and 2021 were extracted.
J Thorac Cardiovasc Surg
September 2025
Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:
Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.
Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.